FDA approves Abbott Labs' Humira for juvenile arthritis

02/25/2008 | Yahoo!

Humira, Abbott Laboratories' injectable drug, has obtained FDA clearance to treat moderate-to-severe juvenile idiopathic arthritis in patients aged 4 years and older. The drug, which is administered every two weeks, is the first biological treatment for the disease to obtain approval since 1999, Abbot said. Humira is already approved for the treatment of rheumatoid arthritis and other conditions in adults.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD